NCT02178189

Brief Summary

Neonatal abstinence syndrome (NAS) symptoms contribute to poor infant weight gain. Early caloric enhancement for infants exposed to methadone is inexpensive, readily available, easy to implement and could improve early outcomes for these high-risk infants. We will conduct a preliminary randomized clinical trial of high-calorie vs. standard-calorie formula for methadone exposed infants to evaluate the adequacy of recruitment, protocol feasibility and estimates of whether high-calorie formula results in more normal patterns of weight loss and gain, less severe NAS symptoms and shorter hospital stays.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
85

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Apr 2010

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2010

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2013

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

June 26, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 30, 2014

Completed
Last Updated

June 30, 2014

Status Verified

June 1, 2014

Enrollment Period

3 years

First QC Date

June 26, 2014

Last Update Submit

June 26, 2014

Conditions

Keywords

prenatal opioid exposureinfantweight gaininfant formula

Outcome Measures

Primary Outcomes (1)

  • Weight Patterns (gain and loss)

    Weight loss and gain patterns will include days to return to birth weight, days to weight nadir (lowest point) and maximum percent weight loss.

    Up to 3 weeks

Secondary Outcomes (1)

  • Neonatal abstinence syndrome (NAS) severity measures

    Up to 3 weeks

Study Arms (2)

Standard-calorie infant formula

ACTIVE COMPARATOR

Infants assigned to this arm were fed standard-calorie infant formula (20 kcal/oz) from 72 hours of life until 21 days of age.

Other: Standard Calorie Infant Formula

High-calorie infant formula

EXPERIMENTAL

Infants assigned to this arm were fed high-calorie infant formula (24 kcal/oz) from 72 hours of life until 21 days of age.

Other: High Calorie Infant formula

Interventions

Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.

High-calorie infant formula

Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.

Standard-calorie infant formula

Eligibility Criteria

Age1 Day - 3 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Infants born to pregnant women, who are 18 to 45 years of age, participating in a licensed methadone maintenance treatment program
  • planning to delivered at Magee if consented during pregnancy or delivered at Magee within the past 48 hours

You may not qualify if:

  • Infants born weighing \<2200 grams or before 35 weeks
  • Multiple gestation pregnancies (eg. twins)
  • Infants with major congenital malformations that could interfere with feeding or weight gain, such as Downs syndrome, cleft lip or palate, congenital heart disease or cystic fibrosis will be excluded.
  • Infants admitted to the NICU longer than 48 hours for a medical condition other than treatment of NAS
  • Women who do not speak English will be excluded because study staff will not be able to communicate effectively.
  • Women who intend to place their infant for adoption
  • Women who plan on feeding their baby soy formula from birth

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Magee-Womens Hospital of UPMC

Pittsburgh, Pennsylvania, 15213, United States

Location

MeSH Terms

Conditions

Neonatal Abstinence SyndromeWeight Gain

Condition Hierarchy (Ancestors)

Infant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSubstance-Related DisordersChemically-Induced DisordersMental DisordersBody Weight ChangesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Debra L Bogen, MD

    University of Pittsburgh

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Pediatrics

Study Record Dates

First Submitted

June 26, 2014

First Posted

June 30, 2014

Study Start

April 1, 2010

Primary Completion

April 1, 2013

Study Completion

December 1, 2013

Last Updated

June 30, 2014

Record last verified: 2014-06

Locations